## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.90 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($950.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025**
- Source: Oncodaily | 20251209T110858 | Bullish | Relevance: 99%
-  Eli Lilly and Company announced the reappointment of Dr. Carolyn R. Bertozzi to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, a Nobel laureate, will serve on the Science and Technology Committee and the Ethics and Compliance Committee, reinforcing Lilly's commitment to scientific excellence and ethical leadership. Her return is expected to significantly contribute to the company's therapeutic innovations, particularly in oncology and immunology.

**2. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company**
- Source: Eli Lilly and Company | 20251211T120833 | Bullish | Relevance: 99%
-  Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial for retatrutide, a triple hormone receptor agonist, showing significant weight loss and improvements in knee osteoarthritis pain and physical function. Participants treated with retatrutide lost an average of up to 28.7% (71.2 lbs) of body weight and experienced up to a 75.8% reduction in WOMAC pain scores. These results highlight retatrutide's potential as an important option for patients with obesity and complications like knee osteoarthritis, with additional Phase 3 readouts expected in 2026.

**3. Eli Lilly (LLY) Stock Is Up, What You Need To Know**
- Source: Finviz | 20251211T170853 | Bullish | Relevance: 98%
-  Eli Lilly's stock jumped after announcing highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide. The drug achieved significant weight loss and improved physical function, surpassing the efficacy of their existing blockbuster, Zepbound. This success reinforces Lilly's strong position in the cardiometabolic health market.

**4. Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition**
- Source: KTLA | 20251209T082800 | Somewhat-Bullish | Relevance: 98%
-  Eli Lilly and Company announced the successful expiration and completion of its tender offer to acquire Adverum Biotechnologies, Inc. Lilly's direct wholly-owned subsidiary, Flying Tigers Acquisition Corporation, purchased approximately 64% of Adverum's outstanding shares at $3.56 per share plus a contingent value right. This acquisition aims to expand gene therapy's potential for age-related conditions, including vision loss, and welcomes Adverum colleagues to Lilly.

**5. Eli Lilly lands in Huntsville with $6 billion mega-site, thousands of jobs and a Made-in-America medicine push**
- Source: Yellowhammer News | 20251209T212058 | Bullish | Relevance: 98%
-  Eli Lilly and Company is investing over $6 billion to build a new pharmaceutical manufacturing facility in Huntsville, Alabama, marking the largest initial investment in the state's history. This mega-site will create approximately 3,450 jobs and focus on domestic production of "small molecule synthetic and peptide medicines," including orforglipron. The project reinforces a "Made in America" push for medicines and is expected to significantly boost local economic activity.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $208M sold (30 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 31.2x attractive for 37% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (8 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $904.9B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 31.2 |
| Current P/E | 42.6 |
| YoY Growth | 36.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -4.9% (minimal 5-day change). Below STRENGTH zone by 8.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.1%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-15.51), momentum weakening. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.86% (CS: 12) | Weak |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | -15.51 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 1.085x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1009.38
- **Stop Loss:** $950.58 (5.8% risk)
- **Target:** $1126.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 23
- **Position Value:** $23,215.74
- **Portfolio %:** 23.22%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*